TL;DR: The Centers for Medicare & Medicaid Services modified NCD 67, the national coverage determination governing cochleostomy with neurovascular transplant for Meniere's disease, effective January 9, 2026. The policy maintains a non-coverage position — this procedure does not meet medical necessity under Medicare. Here's what billing teams need to know.
This update to the CMS cochleostomy with neurovascular transplant coverage policy confirms what NCD 67 has long held: Medicare will not reimburse cochleostomy with neurovascular transplant when billed for treatment of Meniere's disease or Meniere's syndrome. The policy does not list specific CPT or HCPCS codes. But that absence doesn't reduce your exposure — it increases it, because your team has to know what to watch for without a code list to anchor to.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Cochleostomy with Neurovascular Transplant for Meniere's Disease |
| Policy Code | NCD 67 |
| Change Type | Modified |
| Effective Date | 2026-01-09 |
| Impact Level | Medium — highest exposure for ENT and neurotology billing teams |
| Specialties Affected | Otolaryngology (ENT), Neurotology, Audiology |
| Key Action | Flag any claim for cochleostomy with neurovascular transplant billed to Medicare — this procedure is non-covered under NCD 67 and will result in claim denial |
CMS Cochleostomy with Neurovascular Transplant Coverage Criteria and Medical Necessity Requirements 2026
NCD 67 in the Medicare system is the national coverage determination that addresses cochleostomy with neurovascular transplant as a treatment for Meniere's disease. The coverage policy is straightforward: Medicare does not cover this procedure. Full stop.
CMS bases this position on a lack of scientific evidence supporting the safety and effectiveness of cochleostomy with neurovascular transplant for Meniere's syndrome. This is not a prior authorization issue — there's no pathway to get the procedure approved with additional documentation. No prior authorization process applies here because the procedure is categorically excluded from coverage.
To understand why this matters in practice, you need to understand the clinical context. Meniere's disease is a common cause of paroxysmal vertigo — sudden, recurring episodes of severe dizziness. Medicare recognizes two surgical procedures as legitimate treatments when medical management fails: decompression of the endolymphatic hydrops and labyrinthectomy. Those two procedures can meet medical necessity criteria under appropriate circumstances.
Cochleostomy with neurovascular transplant is not on that list. CMS has reviewed the evidence and found none supporting its use. That's the policy's language, and it's the position your billing team needs to internalize before any claim leaves your system.
The real issue here is that Meniere's disease patients often cycle through multiple treatment approaches. A surgeon might document cochleostomy with neurovascular transplant as a last resort after other options failed. That clinical rationale doesn't change Medicare's coverage policy. Medical necessity, as CMS defines it, requires scientific evidence of safety and effectiveness — and CMS has determined this procedure lacks both.
CMS Cochleostomy with Neurovascular Transplant Exclusions and Non-Covered Indications
CMS excludes cochleostomy with neurovascular transplant from Medicare coverage for any indication related to Meniere's disease or Meniere's syndrome. This is a blanket non-coverage determination — not a site-of-service restriction, not a frequency limitation, not a documentation gap you can fix.
The clinical picture doesn't change the billing outcome. Whether the patient has had Meniere's disease for two years or twenty, whether they've failed every recognized medical treatment, whether the surgeon documents extensive clinical justification — none of that satisfies CMS's coverage standard for this procedure. CMS reviewed the evidence and concluded there is no scientific basis to support reimbursement.
This policy falls under the Physicians' Services benefit category in Medicare. That means it applies to physician billing, not just facility claims. If your practice bills Part B for surgical services, this non-coverage determination applies to your claims.
There is no waiver process, no local coverage determination that overrides this NCD, and no Medicare Administrative Contractor that can approve what a national coverage determination explicitly excludes. A MAC cannot approve what NCD 67 prohibits. If you're seeing any internal guidance suggesting otherwise, loop in your compliance officer before submitting a claim.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Meniere's disease — cochleostomy with neurovascular transplant | Not Covered | Not listed in policy | CMS finds no scientific evidence of safety or effectiveness; categorically excluded |
| Meniere's disease — decompression of endolymphatic hydrops | Recognized surgical treatment | Not listed in NCD 67 | CMS acknowledges this as a legitimate surgical option when medical treatment fails |
| Meniere's disease — labyrinthectomy | Recognized surgical treatment | Not listed in NCD 67 | CMS acknowledges this as a legitimate surgical option when medical treatment fails |
| Meniere's disease — medical management | Standard first-line treatment | Not listed in NCD 67 | Surgery indicated only after medical treatment fails |
CMS Cochleostomy with Neurovascular Transplant Billing Guidelines and Action Items 2026
The modified effective date is January 9, 2026. Your team needs to act before claims hit the payer.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for any cochleostomy with neurovascular transplant procedures billed to Medicare. This applies to all claims submitted on or after January 9, 2026. If your practice performs this procedure, those claims will face claim denial under NCD 67. |
| 2 | Brief your ENT and neurotology surgeons on NCD 67's non-coverage position. Surgeons sometimes assume that thorough documentation of medical necessity will overcome a payer's objection. Under NCD 67, there is no documentation that changes the outcome. The procedure is non-covered regardless of clinical justification. |
| 3 | Update your billing guidelines and internal payer reference materials to reflect the January 9, 2026 modification. Even if your practice has been following NCD 67 for years, a policy modification is your trigger to confirm everyone on your revenue cycle team has current information. |
| 4 | Review your ABN (Advance Beneficiary Notice) processes for this procedure. If a Medicare patient wants cochleostomy with neurovascular transplant and your practice plans to perform it, you must issue a properly executed ABN before the procedure. The patient needs to understand Medicare will not pay and that they're personally responsible for the cost. A missing or defective ABN means your practice absorbs the cost of a non-covered service. |
| 5 | Do not attempt to bill for cochleostomy with neurovascular transplant under a related or adjacent code. Because the policy does not list specific CPT or HCPCS codes, some billing teams might consider submitting a claim under a loosely related surgical code. This approach creates false claim exposure. The non-coverage determination applies to the service itself — not to a specific code number. Bill the service accurately or don't bill Medicare at all. |
| 6 | Check whether your payer mix includes Medicare Advantage plans. Medicare Advantage plans must cover at minimum what original Medicare covers — but they can impose additional restrictions. A cochleostomy with neurovascular transplant claim submitted to a Medicare Advantage plan carries the same non-coverage risk as a traditional Medicare claim, plus the plan's own additional rules. Check each plan's billing guidelines separately. |
If your practice has questions about how NCD 67 applies to specific surgical documentation or a patient situation you're facing right now, talk to your compliance officer before the claim goes out.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cochleostomy with Neurovascular Transplant Under NCD 67
A Note on Code Availability
The NCD 67 policy document does not list specific CPT codes, HCPCS codes, or ICD-10-CM diagnosis codes. This is not unusual for older National Coverage Determinations — CMS sometimes issues coverage guidance at the procedure level without anchoring it to specific code sets.
The absence of listed codes does not limit the policy's reach. NCD 67 applies to cochleostomy with neurovascular transplant as a service. The procedure carries the non-covered status regardless of which CPT code your team assigns to the claim.
What This Means for Your Coding Team
Because no codes are specified, your coding team carries more responsibility here than usual. They need to recognize cochleostomy with neurovascular transplant in operative documentation and flag it for review — not just look for a code on a watch list.
Train your coders to identify the procedure by name and by description in operative notes. Any surgical claim involving cochleostomy combined with neurovascular transplant language, billed to Medicare for a patient with Meniere's disease or Meniere's syndrome as the primary diagnosis, falls under NCD 67's non-coverage determination.
If you're unsure which CPT codes your surgeons are currently using to capture this service, pull a claims history report filtered by Meniere's disease diagnosis codes and review the associated procedure codes. That audit will tell you whether cochleostomy with neurovascular transplant billing has been occurring in your practice and whether prior claims need review.
Your compliance officer should be involved in that audit. This is exactly the kind of retroactive review that protects your practice.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.